Zacks Research Weighs in on STERIS’s Q1 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Research analysts at Zacks Research lifted their Q1 2026 earnings per share estimates for shares of STERIS in a report issued on Tuesday, February 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $2.31 per share for the quarter, up from their previous estimate of $2.27. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q2 2026 earnings at $2.36 EPS, Q1 2027 earnings at $2.62 EPS, Q2 2027 earnings at $2.69 EPS, Q3 2027 earnings at $2.81 EPS and FY2027 earnings at $10.72 EPS.

A number of other brokerages have also recently commented on STE. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Stephens reaffirmed an “overweight” rating and set a $240.00 target price on shares of STERIS in a report on Thursday, February 6th. Piper Sandler increased their price target on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Thursday, February 6th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, STERIS has an average rating of “Moderate Buy” and a consensus price target of $258.75.

STERIS Trading Down 0.4 %

NYSE:STE opened at $222.97 on Thursday. The company has a market capitalization of $21.91 billion, a P/E ratio of 47.34 and a beta of 0.84. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. STERIS has a 12 month low of $197.82 and a 12 month high of $248.24. The firm has a fifty day simple moving average of $214.13 and a 200-day simple moving average of $223.13.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be paid a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a yield of 1.02%. STERIS’s dividend payout ratio is currently 48.41%.

Hedge Funds Weigh In On STERIS

A number of large investors have recently added to or reduced their stakes in STE. Ashton Thomas Securities LLC purchased a new stake in shares of STERIS during the third quarter worth about $25,000. Avalon Trust Co acquired a new position in shares of STERIS during the fourth quarter valued at approximately $30,000. Human Investing LLC purchased a new position in shares of STERIS in the fourth quarter valued at approximately $31,000. Anfield Capital Management LLC boosted its stake in shares of STERIS by 100.0% in the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 91 shares during the last quarter. Finally, Central Pacific Bank Trust Division increased its position in shares of STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 76 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.